Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 2Breast Neoplasms 2Uterine Cervical Dysplasia 1Sarcoma 1Polycystic Ovary Syndrome 1Peripheral Nervous System Diseases 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Leukemia 1Insulin Resistance 1Diabetes Mellitus 1Central Nervous System Neoplasms 1Cardiovascular Diseases 1Cardiotoxicity 1Burns 1

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × Fenofibrate × Clear all
NCT01574131 2019-11-29

Acute and Long-Term Outcome Investigations of Fenofibrate on Severely Burned Patients

The University of Texas Medical Branch, Galveston

Phase 4 Terminated
3 enrolled

Burns, Insulin Resistance, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡